Identification of signaling pathways associated with cancer protection in Laron syndrome

Endocrine-Related Cancer

Volumn 23, Issue 5, 2016, Pages 399-410

  Lapkina Gendler, Lena ^a   Rotem, Itai ^a   Pasmanik Chor, Metsada ^a   Gurwitz, David ^a   Sarfstein, Rive ^a   Laron, Zvi ^b   Werner, Haim ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

Author keywords

Cancer protection; Dwarfism; Growth hormone receptor; Insulin like growth factor 1; Laron syndrome

Indexed keywords

JANUS KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SOMATOMEDIN C; SOMATOMEDIN C RECEPTOR; STAT PROTEIN; IGF1 PROTEIN, HUMAN; IGF1R PROTEIN, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PTEN PROTEIN, HUMAN; SOMATOMEDIN RECEPTOR; SP1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR SP1; TRANSCRIPTOME;

ADULT; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER PREVENTION; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENOME-WIDE ASSOCIATION STUDY; HUMAN; HUMAN CELL; LARON SYNDROME; LYMPHOBLASTOID CELL; METABOLIC REGULATION; OXIDATIVE STRESS; SIGNAL TRANSDUCTION; CELL LINE; GENETICS; METABOLISM; MIDDLE AGED; NEOPLASM;

ADULT; APOPTOSIS; AUTOPHAGY; CELL CYCLE; CELL LINE; CELL PROLIFERATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; LARON SYNDROME; MIDDLE AGED; NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RECEPTORS, SOMATOMEDIN; SIGNAL TRANSDUCTION; SP1 TRANSCRIPTION FACTOR; TRANSCRIPTOME;

EID: 84977125920     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-16-0054     Document Type: Article

References (40)

1. Amichay K, Kidron D, Attias-Geva Z, Schayek H, Sarfstein R, Fishman A, Werner H &Bruchim I 2012 BRCA1 is expressed in uterine serous carcinoma (USC) and controls insulin-like growth factor-I receptor (IGF-IR) gene expression in USC cell lines. International Journal of Gynecological Cancer 22 748-754. (doi:10.1097/ IGC.0b013e318254011f)
2. Amselem S, Duquesnoy P, Attree O, Novelli G, Bousnina S, Postel-Vinay MC &Goossens M 1989 Laron dwarfism and mutations of the growth hormone-receptor gene. New England Journal of Medicine 321 989-995. (doi:10.1056/NEJM198910123211501)
3. Baserga R, Peruzzi F &Reiss K 2003 The IGF-1 receptor in cancer biology. International Journal of Cancer 107 873-877. (doi:10.1002/ ijc.11487)
4. Beitner-Johnson D, Werner H, Roberts CT Jr &LeRoith D 1995 Regulation of insulin-like growth factor I receptor gene expression by Sp1: Physical and functional interactions of Sp1 at GC boxes and at a CT element. Molecular Endocrinology 9 1147-1156.
5. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH &Pollak M 1998 Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279 563-566. (doi:10.1126/science.279.5350.563)
6. Cohen P, Rogol AD, Deal CL, Saenger P, Reiter EO, Ross JL, Chernausek SD, Savage MO, Wit JM &Consensus Workshop participants 2008 Consensus statement on the diagnosis and treatment of children with idiopathis short stature: a summary of the Growth Hormone Research Society, The Lawson Wilkins Pediatric Endocrine Society and the European Society for Pediatric Endocrinology Workshop. Journal of Clinical Endocrinology and Metabolism 93 4210-4217.
7. Domene H, Bengolea SV, Martinez AS, Ropelato MG, Pennisi P, Scaglia P, Heinrich J &Jasper H 2004 Deficiency of the circulating IGF system associated with inactivation of the acid-labile subunit gene. New England Journal of Medicine 350 570-577. (doi:10.1056/NEJMoa013100)
8. Godowski PJ, Leung DW, Meacham LR, Galgani JP, Hellmiss R, Keret R, Rotwein PS, Parks JS, Laron Z &Wood WI 1989 Characterization of the human growth hormone receptor gene and demonstration of a partial gene deletion in two patients with Laron-type dwarfism. PNAS 86 8083-8087. (doi:10.1073/pnas.86.20.8083)
9. Green J, Cairns BJ, Casabonne D, Wright FL, Reeves G, Beral V &Million women study collaborators 2011 Height and cancer incidence in the Million Women Study: prospective cohort, and meta-analysis of prospective studies of height and total cancer risk. Lancet Oncology 12 785-794. (doi:10.1016/S1470-2045(11)70154-1)
10. Guevara-Aguirre J, Balasubramanian P, Guevara-Aguirre M, Wei M, Madia F, Cheng CW, Hwang D, Martin-Montalvo A, Saavedra J, Ingles S, et al. 2011 Growth hormone receptor deficiency is associated with a major reduction in pro-aging signaling, cancer, and diabetes in humans. Science Translational Medicine 3 70ra13.
11. Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE &Pollak M 1998 Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351 1393-1396. (doi:10.1016/S0140-6736(97)10384-1)
12. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U &Speed TP 2003 Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4 249-264. (doi:10.1093/biostatistics/4.2.249)
13. Klammt J, Pfaffle R, Werner H &Kiess W 2008 IGF signaling defects as causes of growth failure and IUGR. Trends in Endocrinology and Metabolism 19 197-205. (doi:10.1016/j.tem.2008.03.003)
14. Kofoed EM, Hwa V, Little B, Woods KA, Buckway CK, Tsubaki J, Pratt KL, Bezrodni L, Jasper H, Tepper A, et al. 2003 Growth hormone insensitivity associated with a STAT5b mutation. New England Journal of Medicine 349 1139-1147. (doi:10.1056/NEJMoa022926)
15. Laron Z 1999 Natural history of the classical form of primary growth hormone resistance (Laron syndrome). Journal of Pediatric Endocrinology and Metabolism 12 231-249.
16. Laron Z 2004 Extensive personal experience. Laron syndrome (primary growth hormone resistance or insensitivity): the personal experience 1958-2003. Journal of Clinical Endocrinology and Metabolism 89 1031-1044. (doi:10.1210/jc.2003-031033)
17. Laron Z &Kopchik JJ 2011 Laron Syndrome-From Man to Mouse: Springer-Verlag.
18. Laron Z, Pertzelan A &Mannheimer S 1966 Genetic pituitary dwarfism with high serum concentration of growth hormone-A new inborn error of metabolism? Israel Journal of Medical Sciences 2 152-155.
19. LeRoith D, Bondy C, Yakar S, Liu J-L &Butler A 2001 The Somatomedin hypothesis: 2001. Endocrine Reviews 22 53-74. (doi:10.1210/ edrv.22.1.0419)
20. LeRoith D &Roberts CT Jr 2003 The insulin-like growth factor system and cancer. Cancer Letters 195 127-137. (doi:10.1016/S0304-3835(03)00159-9)
21. LeRoith D &Yakar S 2007 Mechanisms of disease: metabolic effects of growth hormone and insulin-like growth factor-1. Nature Clinical Practice in Endocrinology and Metabolism 3 302-310. (doi:10.1038/ ncpendmet0427)
22. Mizushima N &Yoshimori T 2007 How to interpret LC3 immunoblotting. Autophagy 3 542-545. (doi:10.4161/auto.4600)
23. Moscat J &Diaz-Meco MT 2009 p62 at the crossroads of autophagy, apoptosis, and cancer. Cell 137 1001-1004. (doi:10.1016/j. cell.2009.05.023)
24. Pollak M 2008 Insulin and insulin-like growth factor signalling in neoplasia. Nature Reviews Cancer 8 915-928. (doi:10.1038/nrc2536)
25. Pollak M 2012 The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nature Reviews Cancer 12 159-169.
26. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM &Egger M 2004 Insulin-like growth factor-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363 1346-1353.
27. Rosenfeld RG 2005 The molecular basis of idiophatic short stature. Growth Hormone and IGF Research 15 (Suppl A) S3-5.
28. Rosenfeldt MT &Ryan KM 2011 The multiple roles of autophagy in cancer. Carcinogenesis 32 955-963. (doi:10.1093/carcin/bgr031)
29. Salmon WD &Daughaday WH 1957 A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro. Journal of Laboratory and Clinical Medicine 49 825-836.
30. Shevah O &Laron Z 2006 Genetic analysis of the pedigrees and molecular defects of the GH-receptor gene in the Israeli cohort of patients with Laron syndrome. Pediatric Endocrinology Reviews 3 (Suppl 3) 489-497.
31. Shevah O &Laron Z 2007 Patients with congenital deficiency of IGF-I seem protected from the development of malignancies: a preliminary report. Growth Hormone and IGF Research 17 54-57. (doi:10.1016/j.ghir.2006.10.007)
32. Steuerman R, Shevah O &Laron Z 2011 Congenital IGF1 deficiency tends to confer protection against post-natal development of malignancies. European Journal of Endocrinology 164 485-489. (doi:10.1530/EJE-10-0859)
33. Wang Z, Prins GS, Coschigano KT, Kopchick JJ, Green JE, Ray VH, Hedayat S, Christov KT, Unterman TG &Swanson SM 2005 Disruption of growth hormone signaling retards early stages of prostate carcinogenesis in the C3(1)/T antigen mouse. Endocrinology 146 5188-5196. (doi:10.1210/en.2005-0607)
34. Werner H 2009 The pathophysiological significance of IGF-I receptor overexpression: new insights. Pediatric Endocrinology Reviews 7 2-5.
35. Werner H 2012 Tumor suppressors govern insulin-like growth factor signaling pathways: implications in metabolism and cancer. Oncogene 31 2703-2714. (doi:10.1038/onc.2011.447)
36. Werner H &Bruchim I 2009 The insulin-like growth factor-I receptor as an onogene. Archives of Physiology and Biochemistry 115 58-71.
37. Werner H &Bruchim I 2012 IGF-1 and BRCA1 signalling pathways in familial cancer. Lancet Oncology 13 e537-544.
38. Werner H, Karnieli E, Rauscher FJ III &LeRoith D 1996 Wild type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. PNAS 93 8318-8323. (doi:10.1073/ pnas.93.16.8318)
39. Woods KA, Camacho-Hubner C, Savage MO &Clark AJL 1996 Intrauterine growth retardation and postnatal growth failure associated with deletion of the insulin-like growth factor I gene. New England Journal of Medicine 335 1363-1367. (doi:10.1056/NEJM199610313351805)
40. Zhang X, Mehta RG, Lantvit DD, Coschigano KT, Kopchick JJ, Green JE, Hedayat S, Christov KT, Ray VH, Unterman TG, et al. 2007 Inhibition of estrogen-independent mammary carcinogenesis by disruption of growth hormone signaling. Carcinogenesis 28 143-150. (doi:10.1093/carcin/bgl138)